AstraZeneca's Arthritis Drug Succeeds in Phase 3 Trial

AstraZeneca's (NYSE: AZN  ) phase 3 study of the effectiveness and safety of developmental rheumatoid arthritis drug fostamatinib succeeded in meeting two primary endpoints. The OSKIRA-1 trial showed that fostamatinib increased ACR20 response rates in two different patient groups, according to a statement on the matter from the company. (ACR scores are used in measuring changes in rheumatoid arthritis symptoms.)

The drug also proved safe in the study, with patients tolerating fostamatinib about as well as they had in an earlier phase 2 study. Reported side effects were mild, including diarrhea, nausea, and hypertension.

Dr. Briggs W. Morrison, AstraZeneca's chief medical officer and executive vice president of global medicine development, spoke about fostamatinib's success in the statement, saying, "These top-line results provide important information on the efficacy and safety of fostamatinib and demonstrate that the compound has an effect on the signs and symptoms of rheumatoid arthritis."

The success comes as the rheumatoid arthritis market heats up. Some of the leading treatments for the disease include best-selling immunology drugs such as AbbVie's (NYSE: ABBV  ) Humira and Johnson & Johnson's (NYSE: JNJ  ) Remicade, each of which made more than $6 billion for their companies last year.

Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 08, 2013, at 10:12 AM, klebad wrote:

    According to an article in Business Week, the clinical trial had mixed results in that "the drug did not meet a second goal related to bone erosion and reductions in joint space." The article continues with analyst commentary that "fostamatinib doesn't compare favorably to existing rheumatoid arthritis drugs or to others in clinical development."

Add your comment.

DocumentId: 2349512, ~/Articles/ArticleHandler.aspx, 4/18/2014 12:17:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.